Lilly Releases Pricing Data That Shows Price of Humalog Declined by 8 Percent Since 2014

As government officials continue to scrutinize the high costs of many drugs, particularly the price of life-saving insulin, Indianapolis-based Eli Lilly disclosed data over the weekend that indicates the price for its lead insulin product Humalog dropped by 8 percent over the past five years. In its disclosure, Eli Lilly said that pricing of medications is one of its biggest and most important decisions. Eli Lilly said that across its product portfolio in the United States, the average net price for medications after rebates and discounts are factored in has fallen over the past four years. The net price has declined from 59 percent of list price in 2014 to 46 percent in 2018, Eli Lilly said. Lilly specifically pointed to Humalog, which it said has dropped 8.1 percent during that time frame. Eli Lilly included a chart for Humalog that showed the price for a month’s supply in 2014 was $147. It jumped to $159 in 2015 but then dropped to $133 in 2016. The price in 2017 ticked upwards slightly to $135 for a month’s supply, which is where the price remained in 2018, the company said.